For lipid- and non-lipid-associated obesity as a therapy associated to non-specific anti-obesity drugs the specific LPL activators may substantiate much valuable with respect to skeletal muscle or tissues [620, 621]. The gene discussed is LPL; the disease is obesity disorder.